Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease

6 de janeiro de 2020 atualizado por: ADIR Association

Chronic obstructive pulmonary disease is a leading cause of mortality worldwide.

It is a systemic disease which includes pulmonary, cardiac, muscular, digestive and cognitive impairments.

Pulmonary rehabilitation is a symptomatic treatment to reduce dyspnea and functional incapacity. However, it effects on cognitive dysfunction are not well known.

The aim of this study is to assess the effects of a comprehensive pulmonary rehabilitation program on cognitive dysfunction in patients with severe to very severe chronic obstructive pulmonary disease using the Montreal Cognitive Assessment tool.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Tipo de estudo

Observacional

Inscrição (Real)

56

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • França
      • Bois-Guillaume, França, 76230
        • Bonnevie
      • Le Havre, França, 76600
        • Médrinal

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

N/D

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Every patients with chronic obstructive pulmonary disease referred for pulmonary rehabilitation in ADIR Association (Rouen, France) and the Groupe Hospitalier du Havre (Le Havre, France) will be assessed for eligibility.

Descrição

Inclusion Criteria:

  • Age > 18years;
  • Chronic obstructive pulmonary disease stade III to IV;
  • Referred for pulmonary rehabilitation.

Non Inclusion Criteria:

  • Pregnancy or likely to be;
  • History of psychiatric, neuro-vascular, cognitive disease or cranial trauma;
  • Active alcoholism;
  • Guardianship;
  • Hospitalisation for acute exacerbation of chronic obstructive pulmonary disease in the previous 4 weeks;

Exclusion Criteria:

  • Interruption of the pulmonary rehabilitation program > 15 days;
  • Disruption of the training before the 18th session;
  • Less than 18 sessions in four month.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Pulmonary rehabilitation
The whole population will benefit from a comprehensive pulmonary rehabilitation program, including aerobic training, superior and inferior limb strength training, self-management and add-on to pulmonary rehabilitation as needed (i.e : electrical muscle stimulation, inspiratory muscle training, non-invasive ventilation, high flow nasal canula).
Outro: Pulmonary rehabilitation
See group description.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Baseline cognitive function
Prazo: Cognitive function is assessed at the beginning of the rehabilitation program : day 0
Cognitive function is assessed with the Montreal Cognitive Assessement tool
Cognitive function is assessed at the beginning of the rehabilitation program : day 0
Cognitive function after pulmonary rehabilitation
Prazo: Cognitive function is assessed at the end of the rehabilitation program : day 60
Cognitive function is assessed with the Montreal Cognitive Assessement tool
Cognitive function is assessed at the end of the rehabilitation program : day 60
Cognitive function : follow up
Prazo: Cognitive function is assessed 3 month after rehabilitation : day 150
Cognitive function is assessed with the Montreal Cognitive Assessement tool
Cognitive function is assessed 3 month after rehabilitation : day 150
Change in cognitive function from baseline to the end of pulmonary rehabilitation
Prazo: Change in cognitive function from baseline to the end of pulmonary rehabilitation is assessed with end of pulmonary rehabilitation minus baseline values (day 60 - day 0)
Cognitive function is assessed with the Montreal Cognitive Assessement tool
Change in cognitive function from baseline to the end of pulmonary rehabilitation is assessed with end of pulmonary rehabilitation minus baseline values (day 60 - day 0)
Change in cognitive function from the end of pulmonary rehabilitation to 3 month of follow up
Prazo: Change in cognitive function from the end of pulmonary rehabilitation to 3 month of follow up is assessed with the 3 month of follow minus the end of pulmonary rehabilitation values (day 150 - day 60)
Cognitive function is assessed with the Montreal Cognitive Assessement tool
Change in cognitive function from the end of pulmonary rehabilitation to 3 month of follow up is assessed with the 3 month of follow minus the end of pulmonary rehabilitation values (day 150 - day 60)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Anxiety and depression : baseline
Prazo: Anxiety and depression are assessed at the beginning of the rehabilitation program : day 0
Anxiety and depression are assessed with the Hospital Anxiety and Depression scale (HAD).
Anxiety and depression are assessed at the beginning of the rehabilitation program : day 0
Anxiety and depression : end of pulmonary rehabilitation
Prazo: Anxiety and depression are assessed at the end of the rehabilitation program : day 60
Anxiety and depression are assessed with the Hospital Anxiety and Depression scale (HAD).
Anxiety and depression are assessed at the end of the rehabilitation program : day 60
Anxiety and depression : follow up
Prazo: Anxiety and depression are assesses 3 month after the end of pulmonary rehabilitation program : day 150
Anxiety and depression are assessed with the Hospital Anxiety and Depression scale (HAD).
Anxiety and depression are assesses 3 month after the end of pulmonary rehabilitation program : day 150
Quality of life : baseline
Prazo: Quality of life is assessed at the beginning of the rehabilitation program : day 0
Quality of life is assessed using the Saint Georges Respiratory Questionnaire
Quality of life is assessed at the beginning of the rehabilitation program : day 0
Quality of life : end of pulmonary rehabilitation
Prazo: Quality of life is assessed at the end of the rehabilitation program : day 60
Quality of life is assessed using the Saint Georges Respiratory Questionnaire
Quality of life is assessed at the end of the rehabilitation program : day 60
Quality of life : follow-up
Prazo: Quality of life is assessed 3 month after the end of the rehabilitation program : day 150
Quality of life is assessed using the Saint Georges Respiratory Questionnaire
Quality of life is assessed 3 month after the end of the rehabilitation program : day 150
Functional capacity (six-minute stepper test) : baseline
Prazo: Functional capacity is assessed at the beginning of the rehabilitation program : day 0
Functional capacity is assessed with the six-minute stepper test
Functional capacity is assessed at the beginning of the rehabilitation program : day 0
Functional capacity (six-minute stepper test) : end of pulmonary rehabilitation
Prazo: Functional capacity is assessed at the end of the rehabilitation program : day 60
Functional capacity is assessed with the six-minute stepper test
Functional capacity is assessed at the end of the rehabilitation program : day 60
Functional capacity (six-minute walk test) : baseline
Prazo: Functional capacity is assessed at the beginning of the rehabilitation program : day 0
Functional capacity is assessed with the six-minute walk test
Functional capacity is assessed at the beginning of the rehabilitation program : day 0
Adherence
Prazo: Adherence is assessed at the end of the rehabilitation program : day 60
Adherence to the pulmonary rehabilitation program is assessed by the following equation : number of session performed divided by the number of scheduled sessions
Adherence is assessed at the end of the rehabilitation program : day 60
Relation between the cognitive function and the respiratory function (forced expiratory volume in 1 second)
Prazo: The relation is assessed between baseline demographic data at day 0
Cognitive function is assessed with the Montreal Cognitive Assessement tool and respiratory function is assessed with spirometric evaluation
The relation is assessed between baseline demographic data at day 0

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

ADIR Association

Colaboradores

Groupe Hospitalier du Havre
CHU de Rouen - Accueil

Investigadores

  • Investigador principal: Cuvelier Antoine, Prof, PhD, CHU-Hôpitaux de Rouen - Service de pneumologie, Hôpital de Bois-Guillaume, Rouen, France ; UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France.
  • Cadeira de estudo: Muir Jean-François, Prof, PhD, CHU-Hôpitaux de Rouen - Service de pneumologie, Hôpital de Bois-Guillaume, Rouen, France ; UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France ; ADIR Association, Bois-Guillaume, France.
  • Cadeira de estudo: Tardif Catherine, MD, CHU-Hôpitaux de Rouen - Hôpital de Bois-Guillaume, Service de physiologie urinaire, digestive, respiratoire et sportive, Bois-Guillaume, France
  • Cadeira de estudo: Viacroze Catherine, MD, CHU-Hôpitaux de Rouen - Hôpital de Bois-Guillaume, Service de pneumologie, Bois-Guillaume, France
  • Cadeira de estudo: Debeaumont David, MD, CHU-Hôpitaux de Rouen - Hôpital de Bois-Guillaume, Service de physiologie urinaire, digestive, respiratoire et sportive, Bois-Guillaume, France.
  • Cadeira de estudo: Patout Maxime, MD, UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France ; CHU-Hôpitaux de Rouen - Hôpital de Bois-Guillaume, Service de pneumologie, Bois-Guillaume, France
  • Cadeira de estudo: Lamia Bouchra, Prof, PhD, UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France ; Service de pneumologie, Hôpital de Bois-Guillaume, Rouen, France.
  • Cadeira de estudo: Quieffin Jean, MD, Service de pneumologie, Hôpital Jacques Monod 76290 Montivilliers.
  • Cadeira de estudo: Prieur Guillaume, PT, MsC, Service de pneumologie, Groupe Hospitalier du Havre, Fr
  • Cadeira de estudo: Médrinal Clément, PT, MsC, UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France. Service de réanimation, Groupe Hospitalier du Havre, France
  • Cadeira de estudo: Gravier Francis-Edouard, PT, ADIR Association, Bois-Guillaume, France
  • Cadeira de estudo: Bonnevie Tristan, PT, MsC, ADIR Association, Bois-Guillaume, France ; UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

4 de setembro de 2017

Conclusão Primária (Real)

1 de dezembro de 2019

Conclusão do estudo (Real)

1 de dezembro de 2019

Datas de inscrição no estudo

Enviado pela primeira vez

31 de julho de 2017

Enviado pela primeira vez que atendeu aos critérios de CQ

8 de agosto de 2017

Primeira postagem (Real)

9 de agosto de 2017

Atualizações de registro de estudo

Última Atualização Postada (Real)

7 de janeiro de 2020

Última atualização enviada que atendeu aos critérios de controle de qualidade

6 de janeiro de 2020

Última verificação

1 de janeiro de 2020

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • PR-COPD

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em Pulmonary rehabilitation

Pesquisar ensaios semelhantes

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

CROs by country

CROs in Bosnia & Herzegovina

Condições

Doenças Raras

Intervenções de drogas

Suplementos Alimentares

Patrocinador / Colaboradores

Localizações

3
Se inscrever